创新研发

知识产权和文章著作

　　截至2024年10月，共申请知识产权30多件，其中PCT国际申请5件，已在中国、美国、欧洲等多个国家和地区开展知识产权布局。

 

　　文章著作摘要如下：

Discovery of Reversible, Noncovalent Bruton’s Tyrosine Kinase Inhibitors Targeting BTK C481S Mutation

发表在： ACS Medicinal Chemistry Letters

 Graphical Abstract

Signaling Pathways and Promising Small-Molecule Therapeutic Agents for Ischemic Stroke

发表在： ChemMedChem

Graphical Abstract

Discovery and efficacy study of an ALK inhibitor AMX6001 in anaplastic large cell lymphoma Karpas299 mice models

   发表在：European Journal of Medicinal Chemistry Reports, 2024, Volume 12, 100209.

    Graphical Abstract

  

Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024)

    发表在：RSC Medicinal Chemistry, 2024

    Graphical Abstract

    Prospects of novel fourth-generation EGFR-TKIs overcoming C797S-mediated resistance in non-small cell lung cancer.

     

Discovery of novel, orally bioavailable phenylacetamide derivatives as multikinase inhibitors and in vivo efficacy study in hepatocellular carcinoma animal models

  发表在：Bioorganic & Medicinal Chemistry Letters, 2024, 129971

   Graphical Abstract

   Novel  Phenylacetamide derivatives as multikinase inhibitors.

    

Discovery of novel, selective prostaglandin EP4 receptor antagonists with efficacy in cancer models

     发表在：ACS Medicinal Chemistry Letters 2023

     Graphical Abstract

    

　　

Next-generation Bruton's tyrosine kinase (BTK) inhibitors potentially targeting BTK C481S mutation- Recent developments and Perspectives
　　发表在：Current Topics in Medicinal Chemistry 2022, 22, 1674-1691

　　Graphical Abstract

　　1

 

Design, synthesis of new pyrazolo[3,4-d]pyrimidine derivatives and in vitro evaluation of antiproliferative activity against leukemia cell lines
　　发表在：Russian Journal of Bioorganic Chemistry 2022, 48, 153-162

 

Next generation kinase inhibitors targeting specific biomarkers in non-small cell lung cancer (NSCLC): A recent overview
　　发表在：ChemMedChem2021, 16,2459-2479.

　　Graphical Abstract

　　1

 

Prostaglandin E2 receptor 4 (EP4): a promising therapeutic target for the treatment of cancer and inflammatory diseases
　　发表在：Current Chemical Biology 2021, 15, 50-68

　　Graphical Abstract

　　1

In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models　

　　发表在：Bioorganic Chemistry 2020, 99, 103790

　　Graphical Abstract

　　1

Recent progress and developments of small molecule kinase inhibitors for the treatment of breast cancer
　　发表在：Current Enzyme inhibition2020, 16, 4-19.

　　Graphical Abstract

　　1

Irreversible kinase inhibitors targeting cysteine residues and their applications in cancer therapy
　　发表在：Mini-Rev Med. Chem.  2020, 17, 1732-1753.

　　Graphical Abstract

　　1

Design, synthesis of orally bioavailable novel anaplastic lymphoma kinase (ALK) inhibitor diphenylaminopyrimidine analogs and efficacy study on NCI-H2228 xenografts mice model
　　发表在：Bioorg. Med. Chem. Lett. 2019, 29, 1514-1517.

　　Graphical Abstract

　　1

Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities – Part 1
　　发表在：Bioorg. Med. Chem. Lett. 2019, 29, 591-596.

　　Graphical Abstract

　　1

Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry
　　发表在：Eur. J. Med. Chem.2019, 170, 55-72

　　Graphical Abstract

　　1

Chapter 12. Herpesvirus Polymerase Inhibitors
　　发表在：Book title: VIRAL POLYMERASES Elsevier Publication 2019  p 333-356.

　　Graphical Abstract

　　1